第一作者:
Sara,Feola
第一单位:
Drug Research Program (DRP) ImmunoViroTherapy Lab (IVT), Division of Pharmaceutical Biosciences, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland.;Helsinki Institute of Life Science (HiLIFE), University of Helsinki, Helsinki, Finland.;Translational Immunology Program (TRIMM), Faculty of Medicine Helsinki University, University of Helsinki, Helsinki, Finland.;Digital Precision Cancer Medicine Flagship (iCAN), University of Helsinki, Helsinki, Finland.
作者:
医学主题词
腺病毒科(Adenoviridae);抗原, 肿瘤(Antigens, Neoplasm);癌症疫苗(Cancer Vaccines);人类(Humans);肿瘤(Neoplasms);溶瘤病毒疗法(Oncolytic Virotherapy);溶瘤病毒(Oncolytic Viruses);肽类(Peptides);疫苗, 亚单位(Vaccines, Subunit)
DOI
10.3389/fimmu.2022.826164
PMID
35493448
发布时间
2022-07-16
- 浏览0
Frontiers in immunology
826164页
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文


换一批



